Sign In
Buy TEVA
$32.83
-0.250 (-0.756%)
At Close: Jun 03, 2026
Billionaire Stanley Druckenmiller Jettisoned Shares of Palantir and Nvidia, and Is Piling Into 3 High-Profile Turnaround Stocks
05:06am, Monday, 24'th Mar 2025
Data is abundant, if not overwhelming, on Wall Street. Between earnings season -- the six-week period when a majority of S&P 500 companies unveil their quarterly operating results -- and near-daily ec
Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings
07:00am, Wednesday, 19'th Mar 2025
Stanley Druckenmiller, whose net worth is around $6.9 billion, made most of his fortune as a hedge fund manager, and became a well-known name on Wall Street while working for George Soros until 2000.
Teva Pharmaceutical Industries Limited (TEVA) Leerink's 2025 Global Healthcare Conference (Transcript)
12:15pm, Wednesday, 12'th Mar 2025
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Leerink's 2025 Global Healthcare Conference March 12, 2025 8:40 AM ET Company Participants Richard Francis - CEO Unidentified Company Representative
Teva Pharmaceutical Industries Limited (TEVA) Presents at Barclays 27th Annual Global Healthcare Conference (Transcript)
01:07pm, Tuesday, 11'th Mar 2025
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Barclays 27th Annual Global Healthcare Conference March 11, 2025 8:00 AM ET Company Participants Richard Francis - President & CEO Conference Call P
Teva: Branded Momentum Clashes With Generic Declines And IRA Headwinds
12:27pm, Thursday, 06'th Mar 2025
Teva's Q4 earnings reveal significant headwinds, including declining U.S. generics revenue and rising costs in the API business, impacting overall profitability. Branded drugs like Austedo and Uzedy f
Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March
04:30pm, Monday, 03'rd Mar 2025
TEL AVIV, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at two upcom
The $2 million in new funding is part of a $4 million commitment from Teva, launched in 2022, to expand access to critical mental health services across 10 states The $2 million in new funding is part
PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (E
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Duvakitug (Anti-TL1A) Phase 2 Investors Call to Discuss New Data Presented at ECCO Conference February 24, 2025 8:00 AM ET Company Participants Chri
New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified subgroups across the different doses New endpoints presented include findings on cli
Final Trade: TEVA, JNJ, TJX, BABA
06:27pm, Friday, 21'st Feb 2025
The final trades of the day with the Fast Money traders.
Teva Pharma and Alvotech launch US biosimilar to J&J's Stelara
06:44am, Friday, 21'st Feb 2025
Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the United States.
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
06:00am, Friday, 21'st Feb 2025
PARSIPPANY, N.J. and REYKJAVÍK, Iceland, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Alvotech (NASDAQ: A
Though earnings season -- the roughly six-week period each quarter where a majority of S&P 500 companies reveal their latest operating results -- provides plenty of juicy data for investors to sift th
TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will conduct a conference call and live webcast at 8 am E.T. on Mo
